Results of interferon-alfa therapy in patients with Behcet uveitis

被引:111
|
作者
Tugal-Tutkun, Ilknur [1 ]
Guney-Tefekli, Esra [1 ]
Urgancioglu, Meri [1 ]
机构
[1] Istanbul Univ, Istanbul Fac Med, Dept Ophthalmol, Istanbul, Turkey
关键词
Behcet disease; interferon-alpha; 2a; uveitis;
D O I
10.1007/s00417-006-0346-y
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To report on the results of interferon-alpha 2a (IFN alpha) treatment in patients with Behcet uveitis unresponsive to conventional immunosuppressive therapy. Methods: We retrospectively analyzed the medical records of 44 patients who had been treated with IFN alpha between September 2001 and May 2005. The initial dose of IFN alpha was 6 MU/day in 37 patients (84.1%) and 3 MU/day in 7 patients (15.9%), and was gradually tapered after ocular inflammation was suppressed. Immunosuppressive agents were discontinued. Oral corticosteroids were discontinued or maintained at a dosage of less than 10 mg prednisone equivalent per day. Main outcome measures were recurrence of posterior or panuveitis attacks and changes in visual acuity. Results: Sixteen patients (36.4%) remained relapse free during treatment, whereas 28 (63.6%) patients had recurrent uveitis attacks. Four of these were considered treatment failures and were switched to other treatments. In the remaining 40 patients, the mean duration of treatment was 12.4 +/- 10.8 months (range 3-45 months). In 9 of 40 patients (22.5%) treatment could be discontinued 22.2 +/- 13.4 months after therapy, and 8 (20%) of these patients had sustained remission for up to 24 months. Three patients (7.5%) were switched to other therapies because of side effects. The frequency of uveitis attacks per 6 months was reduced from 1.6 +/- 1.2 to 0.8 +/- 0.9 in 26 patients who had a minimum follow-up of 6 months before and after IFN alpha therapy (p < 0.05). There was a significant improvement in visual acuity and this was preserved throughout follow-up in 38 (95%) of 40 patients. Conclusions: A partial or complete response was obtained with IFN alpha therapy in 91% of Turkish patients with Behcet uveitis refractory to conventional immunosuppressive treatment. Our results suggest that there may be differences in therapeutic efficacy and side-effect profile of IFN alpha in different patient populations. Comparative studies are needed to investigate this hypothesis.
引用
收藏
页码:1692 / 1695
页数:4
相关论文
共 50 条
  • [21] PATTERN OF NEUROBEHAVIORAL DEFICITS ASSOCIATED WITH INTERFERON-ALFA THERAPY FOR LEUKEMIA
    PAVOL, MA
    MEYERS, CA
    REXER, JL
    VALENTINE, AD
    MATTIS, PJ
    TALPAZ, M
    NEUROLOGY, 1995, 45 (05) : 947 - 950
  • [22] Systemic sclerosis after interferon-alfa therapy for myeloproliferative disorders
    Beretta, L
    Caronni, M
    Vanoli, M
    Scorza, R
    BRITISH JOURNAL OF DERMATOLOGY, 2002, 147 (02) : 385 - 386
  • [23] Is it time to make interferon-alfa first-line therapy?
    Kiladjian, J. J.
    LEUKEMIA RESEARCH, 2016, 44 : S9 - S10
  • [24] Interferon-alfa, interferon-λ and hepatitis C
    O'Brien, Thomas R.
    NATURE GENETICS, 2009, 41 (10) : 1048 - 1050
  • [25] The Results of Interferon-Alpha Treatment in Behcet Uveitis
    Eser-Ozturk, Hilal
    Sullu, Yuksel
    OCULAR IMMUNOLOGY AND INFLAMMATION, 2020, 28 (03) : 498 - 504
  • [26] Interferon alfa combined with azathioprine for the uveitis of Behcet's disease:: An open study
    Hamuryudan, V
    Özyazgan, Y
    Fresko, Y
    Mat, C
    Yurdakul, S
    Yazici, H
    ISRAEL MEDICAL ASSOCIATION JOURNAL, 2002, 4 (11): : 928 - 930
  • [27] Interferon-alfa for chronic myeloid leukemia
    Baccarani, M
    Russo, D
    Rosti, G
    Martinelli, G
    SEMINARS IN HEMATOLOGY, 2003, 40 (01) : 22 - 33
  • [28] Low-dose Interferon Alfa-2a Therapy in Severe Uveitis Associated with Behcet Disease REPLY
    Gueudry, Julie
    Terrada, Celine
    Wechsler, Bertrand
    Cassoux, Nathalie
    Huong, Du Le Thi
    Fardeau, Christine
    Lehoang, Phuc
    Piette, Jean-Charles
    Bodaghi, Bahram
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2009, 147 (06) : 1110 - 1110
  • [29] RHABDOMYOLYSIS AFTER TREATMENT WITH INTERFERON-ALFA
    GREENFIELD, SM
    HARVEY, RS
    THOMPSON, RPH
    BRITISH MEDICAL JOURNAL, 1994, 309 (6953): : 512 - 512
  • [30] Multifocal ERG (MERG) changes in patients with ocular Behcet's Disease (BD) during therapy with interferon-alfa 2a (IFNα2a).
    Stuebiger, N
    Koetter, I
    Apfelstedt-Syila, E
    Zrenner, E
    Zierhut, M
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2000, 41 (04) : S782 - S782